Priority review reflects AZUR-1 meeting its primary end point of meaningful, sustained 12-month cCR in dMMR/MSI-H stage ...
As artificial intelligence (AI) becomes more integrated into clinical trial matching, human oversight remains an important ...
Sustained MRD negativity at 12 months was higher with D-VRd, with similar advantages at 24 and 36 months and a lower rate of ...
Primary endpoint results showed no SSE-FS benefit with radium-223 addition (HR 1.46; 1-sided P=.12), while OS, PFS, and ORR ...
Laila Alkhouli, MD, of Cleveland Children's Clinic outlines critical findings from research evaluating how care teams across ...
Because accelerated approval rests on response and durability data from a single-arm trial, the ongoing phase 3 IGNYTE-3 ...
Hearn Jay Cho, MD, explains how immune profiling could inform what impairs T-cell fitness, a crucial consideration when using CAR T-cell therapy or bispecific T-cell engagers. Hearn Jay Cho, MD, PhD, ...
The FDA has granted fast track designation to safusidenib, an oral IDH1 inhibitor, based on durable phase 2 J201 study ...
Experts weigh continuous vs time‑limited CLL therapy, compare acalabrutinib and zanubrutinib, and debate when pirtobrutinib ...
A survey of multiple transplant centers found a lack of consistent use of comprehensive screening for chronic GVHD; lead ...
The FDA has granted breakthrough therapy designation and fast track designation to 68Ga-NYM096, an investigational PET ...
Agentic AI in oncology distills evidence, molecular data, and guidelines to aid therapy decisions, promising smarter, context ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results